The test will be made available to physician clients of Quest Diagnostics in certain regions in the US in March and available nationwide from April 2013.
Panorama is a non-invasive screening test, which can be used at the stage of early ninth week of pregnancy, and provides early information for assessing pregnancy risks.
Panorama uses cell-free fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and monosomy X (Turner syndrome).
Quest Diagnostics Nichols Institute genetics division senior medical director Charles Strom said Cell-free fetal DNA testing is a major advancement in prenatal screening.
"By offering physicians and women access to Panorama, Quest Diagnostics is delivering on its commitment to provide clinically important innovations aligned with guideline-based care," Strom added.